報價延遲最少15分鐘:2026/04/26 01:45 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.11 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.87/-0.96
|
|
企業價值
465.43M
|
| 資產負債 |
|
每股賬面淨值
2.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
35.11M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003and X4P-002 which are CXCR4 antagonists with different properties. |
